Alpha Cognition Inc.
OTC: ACOGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael E. McFadden
- Headquarters
- Vancouver, Canada
- IPO year
- 2021
- Market cap
- $35.7M
- Website
- https://www.alphacognition.com
Loading ACOGF…
Loading profile data…Frequently asked questions about ACOGF
What does Alpha Cognition Inc. (ACOGF) do?
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and...
Where does ACOGF trade?
Alpha Cognition Inc. (ACOGF) trades on the Other OTC.
What sector is ACOGF in?
Alpha Cognition Inc. (ACOGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alpha Cognition Inc.?
Michael E. McFadden is the chief executive officer of Alpha Cognition Inc. (ACOGF).
Where is Alpha Cognition Inc. headquartered?
Alpha Cognition Inc. is headquartered in Canada.
Does ACOGF pay a dividend?
Alpha Cognition Inc. (ACOGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACOGF go public?
Alpha Cognition Inc. (ACOGF) completed its initial public offering in 2021.